Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up



Koziel, Monika, Mazurek, Michal, Teutsch, Christine, Diener, Hans-Christoph, Dubner, Sergio J, Halperin, Jonathan L, Ma, Chang-Sheng, Rothman, Kenneth J, Brandes, Axel, Paquette, Miney
et al (show 6 more authors) (2020) Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up. JOURNAL OF CLINICAL MEDICINE, 9 (6). E1969-.

Access the full-text of this item by clicking on the Open Access link.

Abstract

<h4>Background</h4>We aimed to assess the extent to which drug persistence is better with non-vitamin K antagonist oral anticoagulants (NOACs) than vitamin K antagonists (VKAs) in atrial fibrillation (AF) patients and to estimate the difference in therapy persistence depending on NOAC dosing regimen (once daily (QD) vs. twice daily (BID)).<h4>Methods</h4>Consecutive patients were followed for 1 year in phase III of the GLORIA-AF registry. Drug persistence was defined as the use of OAC without any discontinuation in >30 days or switching to alternative therapy.<h4>Results</h4>Among 21,109 eligible patients in phase III, 17,266 patients who were prescribed OAC at baseline and those who took ≥1 OAC dose were included. The 1-year proportion of patients receiving NOAC and VKA who persisted on treatment was 80% and 75%, respectively. The 1-year persistence with NOACs BID and NOACs QD was 81% and 80%, respectively. Female gender, hypertension, older age, alcohol use, permanent, asymptomatic, and minimally symptomatic AF were associated with better OAC persistence. Region, medication usage predisposing to bleeding, being a current smoker, treatment reimbursement, and proton pump inhibitors were associated with lower OAC persistence.<h4>Conclusions</h4>Drug persistence was higher with NOACs (1-year persistence was 80%) than with VKAs (75%). There was little difference in 1-year persistence between NOAC dosing regimens.

Item Type: Article
Uncontrolled Keywords: atrial fibrillation, dosing frequency, GLORIA-AF, non-vitamin K antagonist oral anticoagulants, oral anticoagulants, vitamin K antagonists
Divisions: Faculty of Health and Life Sciences
Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User: Symplectic Admin
Date Deposited: 06 Jul 2021 08:19
Last Modified: 25 Jan 2024 16:05
DOI: 10.3390/jcm9061969
Open Access URL: https://doi.org/10.3390/jcm9061969
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3128975